Lexicon Pharmaceuticals LXRX Stock options excluded as their inclusion would be anti-dilutive (in shares)
Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares)?
- Lexicon Pharmaceuticals (LXRX) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 8.7M in Q1 2026.
- How has Lexicon Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?
- Lexicon Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 2800.0% year-over-year, from 300K to 8.7M.